The group's principal activity is the development and exploitation of antibody technologies. with the use of the advanced proprietary platform technology, phage display system, they discovered and developed fully human therapeutic antibodies. their phage antibody libraries, currently incorporating more than 100 billion distinct antibodies will form the basis of their strategy to develop a portfolio of antibody-based drugs as new treatments for disease.